Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cagrilintide in Obesity After GLP-1-RA Discontinuation
NCT07607587Phase 1Recruiting
- Sponsor
- Novo Nordisk
- Start
- May 2026
- Primary completion
- Nov 2027
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing Cagrilintide with Placebo (2 arms). Primary endpoint: Percentage of participants on standard dose or higher dose at 26 weeks. Started May 2026; status: recruiting.
02
Drugs
cagrilintide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07607587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07607587.